EyecareX Case Study
Clinical Commercialization & Pricing: Turning Internal Proof Into External Traction
Results At A Glance
Market Proof
Validated demand with a 32‑clinic survey: 80% committed to pilot the MVP, de‑risking external rollout and sharpening investor story.
Go-to-Market (GTM) System
Defined six target segments and built segment‑specific sales playbooks (qualification, demo flow, objection handling). Installed a post‑demo activation cadence and in‑app onboarding.
Pricing & Packaging
Established a tiered entry‑to‑expansion model: $1K/month initial pricing, moving to $3.5K/month with phase 2 launch.
Capital Readiness
Aligned milestones to a $2.5M pre‑seed at a $10M valuation; framed KPIs and a phased ARR plan ($108K by Q1 2025, $800K expansion target, and $1.2M by Q2 2026).
Signal
The tech was promising, but the market was fragmented: varying clinic ownership structures, uneven capacity, heavy onboarding, and regulatory gates (HIPAA/FDA/SOC2).
Narrative and pricing needed to match adoption risk and cash‑flow realities.
Structure
We rebuilt the commercial engine around four pillars:
-
Segmentation & ICP
-
Mapped six segments by ownership and sales‑cycle complexity (owned, personal contacts, Canadian chains, independents at capacity, clinics not at capacity, cold US/EU chains).
-
Prioritized warm paths to speed early external wins.
-
-
Pricing & Packaging
-
Introduced a staged price architecture ($1K entry → $3.5K with PMS) aligned to value unlocks and regulatory milestones.
-
Created offer constructs for pilots (clear success criteria, activation SLAs, outcomes‑based upsell).
-
-
Onboarding & Customer Experience
-
Designed a clinic‑ready onboarding flow (web app configuration, reception/clinician training, CX cadence).
-
Shifted demos from feature tours to operational outcomes (chair‑time reclaimed, reduced admin load, faster triage).
-
Implemented a consistent post‑demo follow‑up rhythm to move trials to activation.
-
-
Investor Narrative & Operating KPIs
-
Built a milestone‑based roadmap with commercialization metrics (activation rates, automation %, ARR milestones).
-
Prepared pitch materials and financial model aligned to a $2.5M pre‑seed at $10M pre‑money.
-
Scale
With proof, pricing clarity, and a lighter lift for clinics:
-
9 clinics live generating operational data and patient throughput (~2,000/month).
-
Demo → activation improved as onboarding standardized and CX systems matured.
-
ARR path formalized: $108K by Q1 2025, expansion to $800K, and V2 targeting 65% automation and $1.2M ARR by Q2 2026.
